Haleon PLC Sponsored ADR (NYSE:HLN) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. reduced its stake in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 3.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,380,373 shares of the company's stock after selling 249,934 shares during the period. Envestnet Asset Management Inc. owned 0.16% of Haleon worth $75,944,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bartlett & CO. Wealth Management LLC boosted its stake in Haleon by 135.9% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company's stock valued at $27,000 after acquiring an additional 1,491 shares during the period. Opal Wealth Advisors LLC acquired a new position in Haleon in the first quarter valued at approximately $29,000. FIL Ltd boosted its stake in Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after acquiring an additional 1,270 shares during the period. Continuum Advisory LLC boosted its stake in Haleon by 152.4% in the first quarter. Continuum Advisory LLC now owns 4,753 shares of the company's stock valued at $49,000 after acquiring an additional 2,870 shares during the period. Finally, Alpine Bank Wealth Management acquired a new position in Haleon in the first quarter valued at approximately $56,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Wall Street Zen upgraded Haleon from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. BNP Paribas raised Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target on the stock in a report on Tuesday, May 27th. Finally, Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a report on Friday, May 9th. Five analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Price Performance

Shares of NYSE:HLN opened at $10.10 on Friday. Haleon PLC Sponsored ADR has a 12 month low of $8.68 and a 12 month high of $11.42. The stock has a market cap of $45.38 billion, a price-to-earnings ratio of 25.90, a PEG ratio of 2.89 and a beta of 0.25. The stock's 50 day moving average price is $10.71 and its 200 day moving average price is $10.16. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.98 and a quick ratio of 0.78.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.